ASH 2022 | Golden Gate: blinatumomab alternating with low-dose chemotherapy for older adults with BCP-ALL
Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares results from the safety arm of the randomized Phase III Golden Gate study (NCT04994717) assessing blinatumomab alternating with low-dose chemotherapy for older adults with newly diagnosed Philadelphia (Ph)-negative B-cell acute lymphoblastic leukemia (BCP-ALL). This regimen was well tolerated, and the study reported that all ten patients had a complete response (CR) after induction. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Other: Advisory Role, Research Funding; Genentech: Other: Advisory Role, Research Funding; Adaptive Biotechnologies: Other: Advisory Role, Research Funding; Spectrum: Research Funding; Pfizer: Other: Advisory Role, Research Funding; Bristol Myers Squibb: Other: Advisory Role, Research Funding; Amgen: Other: Advisory Role, Research Funding; AbbVie: Other: Advisory Role, Research Funding.
